報價延遲最少15分鐘:2024/05/16 15:01 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
67.785 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.36/7.32
|
|
企業價值
106.67B
|
| 資產負債 |
|
每股賬面淨值
14.08
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
27.12B
|
|
每股收益
21.99
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 15:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology. |